A new Seeking Alpha report on Catasys (NASDAQ: CATS) makes a clear case for why the company is a gamechanger at the apex where value-based reimbursement and evidence-based treatment models converge to disrupt the Behavioral Health industry.
The report notes FY 2019 revenues are forecast to rise over 130% YOY as CATS enters the hyper-growth stage with its healthcare cost-shrinking model (versus the traditional cost-growing income model).
CATS provides an evidence-based scalable solution that integrates sophisticated cognitive learning technologies with personalized human engagement to deliver outcomes. In a nutshell, CATS contracts with health insurance carriers to reduce medical costs for “treatment-avoidant” members and collects a percentage of the cost-savings as revenue. In essence, this is the anti-treatment center model, where efficiency and accountability drive revenue growth, a cost-shrinking income model.
Catasys (NASDAQ: CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
To read full newsletter and learn about other top small cap stocks